Independent
Tenure on this board
1.2 yrs
Also a director at
Enliven Therapeutics Inc (ELVN)Bridgebio Oncology Therapeutics Inc (BBOT)
Meeting calendar
IMVT · Annual meeting · Wednesday, August 27, 2025
Immunovant Inc
3 nominees · 3 ballot items.
Three proposals are being voted on: 1) election of the Board's three director nominees for a one-year term; 2) ratification of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2026; and 3) non-binding advisory vote on executive compensation as disclosed in the proxy statement.
Market cap
$7.8B
1Y TSR
+117.8%
Board grade
B-
Record date
Jun 30, 2025
Filing
DEF 14A
Meeting concluded · Aug 27, 2025
Follow how the vote landed and what changed on Immunovant Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORTo elect the Board of Directors’ three nominees for director: Jacob Bauer, Douglas Hughes and Robert Susman, each to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORThe Audit Committee has selected Ernst & Young LLP as Immunovant’s independent registered public accounting firm for the fiscal year ending March 31, 2026, and the stockholders’ ratification is being sought as a matter of good governance.
- 3
Non-Binding, Advisory Vote on Executive Compensation
ManagementBoard: FORThe stockholders are asked to approve, on a non-binding, advisory basis, the compensation of Immunovant’s named executive officers as disclosed in the proxy statement.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
6.5 yrs
Independent
Tenure on this board
1.2 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 5.6% | 11,526,971 | $286M |
| 2 | FMR LLC | 4.7% | 9,630,249 | $239M |
| 3 | FMR LLC | 3.5% | 7,285,041 | $181M |
| 4 | BAKER BROS. ADVISORS LP | 2.7% | 5,457,881 | $136M |
| 5 | STATE STREET CORP | 2.2% | 4,537,929 | $113M |
| 6 | TCG Crossover Management, LLC | 2.2% | 4,457,988 | $111M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8% | 3,704,905 | $92M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 3,620,050 | $90M |
| 9 | T. Rowe Price Investment Management, Inc. | 1.8% | 3,612,860 | $90M |
| 10 | ARMISTICE CAPITAL, LLC | 1.7% | 3,564,916 | $89M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Immunovant Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Catalyst Pharmaceuticals IncCPRX
Special meeting·Jul 8, 2026·$3.8B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Reference
Frequently asked questions
- When is the Immunovant Inc 2025 annual meeting?
- Immunovant Inc (IMVT) holds its 2025 annual shareholder meeting on Wednesday, August 27, 2025.
- What is the record date for the Immunovant Inc 2025 meeting?
- The record date for the Immunovant Inc 2025 meeting is Monday, June 30, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Immunovant Inc's 2025 meeting?
- The board is presenting 3 director nominees at the Immunovant Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Immunovant Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Immunovant Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.